by Raynovich Rod | Jan 31, 2020 | Biopharmaceuticals, Macro
Update-1 2/3…3:30p EST… Biopharma stocks firm up after a bad week Large caps are strong with Gilead Sciences (GILD) up over 5% on a story about an experimental antiviral therapy for coronavirus China. GILD is one of the leading antiviral companies for...
by Raynovich Rod | Nov 30, 2019 | Biopharmaceuticals
Update-2 …12/3…Biotech among the leading sectors on a sell-off day With NASDAQ off 0.55% and the S&P down 0.68%, biotech stocks were oblivious to the trade worries and had a huge rally driven by gene therapy stocks. The XBI was up 1.47% and most mid...
by Raynovich Rod | Jun 24, 2019 | Biopharmaceuticals, Macro
Update-2… 6/27 2p EDT…Good day for gene therapy stocks My longs CRSP and MGTX are up. Looking better all across the screen in biopharma. Added to ABBV and XNCR yesterday. XBI up but still under $86. Update-1… Another Big Deal in Biotech in a weak...
by Raynovich Rod | Apr 21, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 XLV up from bottom at $86 to $88.63. IBB holding but more choppy at $107 level. Update-2 12p EDT-IBB flattish at $106 as earnings on large caps come in-will be reviewed at end of week. ABBV down 0.8% on Humira concerns:, profit forecast raised EPS gains...
by Raynovich Rod | Apr 15, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 10:45a 4/17…XBI down 3.37% to FEB support at $86. Healthcare issues are spilling over to biotech.Red screen day and all biotechs hit very hard.Drug pricing models are under scrutiny. Update-1…NASDAQ ekes out small gains but large cap biotechs...
by Raynovich Rod | Apr 7, 2019 | Biopharmaceuticals
4/11 ALERT: Need to check out reasons for biotech sell-off; could be proposed drug pricing bills and “affordability board.” See STAT News . See 4/11 chart below for XBI. Choppy pattern returns at resistance with no breakthrough highs. Biopharma stocks...
by Raynovich Rod | Mar 17, 2019 | Biopharmaceuticals
ALERT 3/21/19…BIOGEN (BIIB) down 28% to $233 after dropping Alzheimer’s Disease late stage trial; another failed clinical stage drug in AD. (more later). IBB down 2.5%. ====== 3/20/19…a whipsaw day…Powell comes to market rescue with...
by Raynovich Rod | Mar 6, 2019 | Biopharmaceuticals
Update-3…3/11…Gene Therapy stocks go green screen! Big 5% winners: VYGR NTLA BLUE EDIT See complete list below (paste list into yahoo finance for tracking) Update-2…3/11…Market gets support from 60 Minutes-Powell comments and Gene Therapy;...
by Raynovich Rod | Feb 28, 2019 | Biopharmaceuticals
Update-2…Biotech rally Friday and Gene Therapy stocks One clue to the stealth rally on Friday is this article in Barron’s published Saturday (? hmmm) Why Big Pharma is Diving into Gene Therapy If you cannot access this article and are not a subscriber go...
by Raynovich Rod | Feb 25, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update: 1:40 EST 2/25… Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%. Another big deal as GE sells healthcare business to Danher (DHR) for $21.4B; GE up 8.26%, DHR up 8.38%. ========== M&A Drives Mid and Small Cap Biotechs...